Pharsight

Valcyte patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642911 HOFFMANN LA ROCHE Pharmaceutical dosage forms comprising valganciclovir hydrochloride
Dec, 2027

(4 years from now)

US8889109 HOFFMANN LA ROCHE Pharmaceutical dosage forms comprising valganciclovir hydrochloride
Dec, 2027

(4 years from now)

Valcyte is owned by Hoffmann La Roche.

Valcyte contains Valganciclovir Hydrochloride.

Valcyte has a total of 2 drug patents out of which 0 drug patents have expired.

Valcyte was authorised for market use on 28 August, 2009.

Valcyte is available in for solution;oral dosage forms.

The generics of Valcyte are possible to be released after 11 December, 2027.

Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2009

Treatment: NA

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of VALCYTE before it's drug patent expiration?
More Information on Dosage

VALCYTE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic